hidradenitis suppurativa
Rheumatology · 2016–2025
19decisions
4medicines
12carried consumer input
29individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Immune-mediated inflammatory diseases (IMIDs) in paediatric patients, including juvenile idiopathic arthritis, Crohn disease, ulcerative colitis, psoriasis,… | Jul 2025 | Deferred | 6 individuals |
| bimekizumab Treatment of moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy. | May 2025 | Recommended with restriction | 2 individuals Hidradenitis Suppurativa Australia · Global Healthy Living Foundation Australia |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2024 | Recommended with restriction | none received |
| adalimumab Complex refractory fistulising Crohn disease, severe Crohn disease, moderate to severe ulcerative colitis, moderate to severe hidradenitis suppurativa, and… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| secukinumab Treatment of moderate to severe hidradenitis suppurativa in patients who have failed to respond to antibiotics. | Jul 2023 | Not recommended | 7 individuals |
| secukinumab Treatment of moderate to severe hidradenitis suppurativa in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa… | Nov 2023 | Recommended with restriction | none received |
| adalimumab; upadacitinib Change in restriction levels (Authority Required categories) for adalimumab across multiple indications (rheumatoid arthritis, ankylosing spondylitis,… | Nov 2022 | Noted | 1 individuals |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid arthritis, severe… | Jul 2021 | Recommended with restriction | input received |
| adalimumab Biosimilar to adalimumab for multiple indications including severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe ulcerative… | Jul 2020 | Recommended with restriction | none received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Mar 2020 | Recommended | input received Colitis Australia |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| adalimumab Moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy. | Nov 2019 | Recommended | none received |
| adalimumab Treatment of moderate to severe hidradenitis suppurativa (HS) in adult patients. The 80 mg strength is indicated for maintenance dosing following induction… | Nov 2019 | Recommended | none received |
| adalimumab Biosimilar of adalimumab for all indications for which Humira is currently PBS listed, including severe active rheumatoid arthritis, severe psoriatic… | Jul 2018 | Recommended with restriction | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| adalimumab Treatment of severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's disease, moderate… | Jul 2018 | Recommended with restriction | none received |
| adalimumab Initial treatment of moderate-to-severe hidradenitis suppurativa in patients who have failed adequate trials of systemic antibiotics and have an abscess and… | Jul 2016 | Not recommended | 1 individuals |
| adalimumab Initial treatment of moderate-to-severe hidradenitis suppurativa (HS) in adult patients with inadequate response to conventional HS therapy. | Mar 2016 | Not recommended | 7 individuals |
| adalimumab Treatment of moderate to severe hidradenitis suppurativa in adult patients with inadequate response to conventional systemic therapy. | Nov 2016 | Deferred | 4 individuals |
Who spoke
Colitis Australia · Hidradenitis Suppurativa Australia · Global Healthy Living Foundation Australia
What the PBS pays
$417M in government benefit over 2024–25, across 514,736 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adalimumab | $241.9M |
| secukinumab | $120.2M |
| bimekizumab | $54.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| bimekizumabBimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) | TA1028 | terminated | 2025-01 |
| secukinumabSecukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | recommended restricted | 2023-12 |
| adalimumabAdalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | recommended restricted | 2016-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 12 of 19 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.